NCT01009216View on ClinicalTrials.gov

A Study of ABT-384 Levels and Pharmacodynamic Activity Measured in Cerebrospinal Fluid

PHASE1CompletedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions

Healthy

Interventions

DRUG

ABT-384

Doses will be administered daily for 5 days.

Trial Locations (1)

91206

Site Reference ID/Investigator# 23882, Glendale

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Abbott

INDUSTRY